Maxim upbeat on Atossa Therapeutics after recent updates
Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enrollment...
Source: proactiveinvestors.com
Kyle Guse News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kyle Guse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kyle Guse Today - Breaking & Trending Today
Atossa Therapeutics Inc taps seasoned life sciences executive from its board to be CFO
Atossa Therapeutics Inc (NASDAQ:ATOS) has found its new chief financial officer in veteran life sciences executive and longtime board member Greg Weaver. ...
Source: proactiveinvestors.com
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Two Phase 2 trials investigating -endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended... | May 15, 2023
Source: marketscreener.com
Atossa Therapeutics, Inc. Receives Authorization from FDA
Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter...
Source: globenewswire.com
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com